Solitary Fibrous Tumors News - LARVOL Sigma

Solitary Fibrous Tumors

Welcome, Profile Billing Logout

4 Mechanisms of Action

||||||||||  sorafenib / Generic mfg.
Trial completion, Metastases:  S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas (clinicaltrials.gov) -  Oct 2, 2012
P2, N=51, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed

|||||||||| Trial termination: Yoga Therapy in Treating Patients With Malignant Brain Tumors (clinicaltrials.gov) - Sep 27, 2012
P=N/A, N=9, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Not yet recruiting --> Terminated; Slow Accruals

|||||||||| Enrollment change: Yoga Therapy in Treating Patients With Malignant Brain Tumors (clinicaltrials.gov) - Sep 27, 2012
P=N/A, N=9, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Terminated; Slow Accruals N=20 --> 9

||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment change, Metastases:  Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  Sep 19, 2012
P2, N=132, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=20 --> 9 N=44 --> 132

||||||||||  pegylated liposomal doxorubicin / Generic mfg., ifosfamide / Generic mfg.
Trial completion, Combination therapy, Metastases:  Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) -  Sep 19, 2012
P1, N=28, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=44 --> 132 Active, not recruiting --> Completed

||||||||||  imatinib / Generic mfg.
Trial completion, Metastases:  STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma (clinicaltrials.gov) -  Sep 19, 2012
P2, N=91, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion, Metastases:  Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  Sep 19, 2012
P2, N=132, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  bortezomib / Generic mfg., temozolomide / Generic mfg.
Enrollment change:  Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment (clinicaltrials.gov) -  Sep 6, 2012
P1, N=25, Completed,  Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=72 --> 25

||||||||||  bortezomib / Generic mfg., temozolomide / Generic mfg.
Trial completion:  Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment (clinicaltrials.gov) -  Sep 6, 2012
P1, N=25, Completed,  Sponsor: City of Hope Medical Center
N=72 --> 25 Active, not recruiting --> Completed

||||||||||  brostallicin (PNU-166196) / SOBI
Trial completion, Metastases:  Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) -  Jul 16, 2012
P2, N=64, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion, Metastases: Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 16, 2012
P2, N=39, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  sunitinib / Generic mfg.
Enrollment closed:  Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma (clinicaltrials.gov) -  Jul 15, 2012
P2, N=50, Active, not recruiting,  Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery:  SWOG-EORTC-62933: Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma (clinicaltrials.gov) -  Jul 9, 2012
P3, N=340, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  ZFN modified T cell (SB-313) / Sangamo Therap
Enrollment change, Combination therapy:  Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 (clinicaltrials.gov) -  Jun 26, 2012
P1, N=6, Completed,  Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=10 --> 6

||||||||||  ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases:  Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) -  Jan 18, 2012
P3, N=780, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=10 --> 6 Active, not recruiting --> Completed